Compare compounds

PT-141

Vials

10 mg

Dosing data

Lab reference — not listed

Melanotan II

Vials

10 mg

Dosing data

Lab reference — not listed

PT-141

PT-141 (bremelanotide) is a melanocortin receptor agonist, acting mainly on central MC4 receptors involved in sexual motivation.

Melanotan II

Melanotan II is a non-selective melanocortin receptor agonist. MC1 activity increases melanin (tanning); central melanocortin activity produces erections and sexual stimulation.

PT-141

• RECONNECT (two phase 3 trials, 1,267 premenopausal women with hypoactive sexual desire disorder): significant increases in desire and reductions in related distress vs placebo.
• Integrated safety data (1,247 women): nausea was the main reason for stopping treatment.

Melanotan II

• An early phase 1 study in healthy men reported increased facial and body pigmentation, spontaneous erections, nausea, and a stretching and yawning complex.
• A qualitative study of 623 online forum entries found use driven by tanning goals, frequent misinformation and concerning practices with unregulated products.

PT-141

• FDA-approved (as Vyleesi) only for hypoactive sexual desire disorder in premenopausal women; research-grade material is not that product.
• Most common adverse events: nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%) and headache (11.3% vs 1.9%). Small, transient blood-pressure increases were seen.
• Focal hyperpigmentation was rare at labelled use but affected more than a third of participants after up to 16 consecutive daily administrations.

Melanotan II

• Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
• Case reports link unregulated use to rhabdomyolysis, kidney failure and renal infarction.

PT-141

2 references · view

Melanotan II

3 references · view